



Olivier Michielin

Contact

Olivier Michielin

Publications (6)

de Joode K, Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard C, Läubli H, Michielin O, von Moos R, Jörger M, Levesque M, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex S, Mathijssen R, Metaxas Y. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. *J Immunother* 2024; 47:190-194.

Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. *J Clin Oncol* 2022; 40:3741-3749.

Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). *Cancers (Basel)* 2022; 14

Kunstfeld R, Moser E, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori F, Pfeilstöcker M, Raut C, Michielin O, Meran J, Lenz H, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer P, Markham M, Markman B, Mayerhoefer M, Remick S, Robson M, Rutkowski P, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber J, Wildiers H, Strasser F, Stiefel F, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll H, Schnipper L, Sessa C, Shapiro C, Steele J, Sternberg C, Yarden Y, Dittrich C, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close J, Coiffier B, Connolly R, Coupland S, Banerjee S, Awada A, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz J, Österlund P, Pavlidis N, Purkayne G, De Petris L, De Santis M, de Vries E, Hahn S, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones D, Jost L, Keilholz U, Khan S, Kiss A, Grothey A, Gopalan P, Dizon D, Duff J, Duska L, Eniu A, Ernstoff M, Felip E, Fey M, Gilbert J, Girard N, Glaudemans A, Köhne C. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. *ESMO Open* 2016; 1:e000097.

Demaria O, Speiser D, Modlin R, Martinon F, Petrova T, Hwu P, Michielin O, Gaide O, Flatz L, Di Domizio J, Gestermann N, Coso S, De Gassart A, Gilliet M. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. *Proc Natl Acad Sci USA* 2015; 112:15408-13.

Schraml P, Moch H, Schläppi M, Seifert B, Michielin O, Dummer R, Ochsenbein A, Simcock M, Mihic-Probst D, von Teichman A, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. *Oncol Rep* 2012

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch